Engineered Escherichia coli as new source of flavonoids and terpenoids

Food Research International

Volumn 54, Issue 1, 2013, Pages 1084-1095

  Putignani, Lorenza ^a   Massa, Ornella ^a   Alisi, Anna ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Cancer; Diabetes; Escherichia coli; Flavonoids; Metabolic engineering; Terpenoids

Indexed keywords

ANTI-INFLAMMATORIES; BIOCHEMICAL ACTIVITY; CANCER; CLINICAL APPLICATION; ENGINEERED BIOSYNTHESIS; ENGINEERED ESCHERICHIA COLI; MICROBIAL SOURCES; TERPENOIDS;

BIOCHEMISTRY; BIOSYNTHESIS; CELL ENGINEERING; DISEASES; FLAVONOIDS; LIPIDS; MEDICAL PROBLEMS; METABOLIC ENGINEERING;

ESCHERICHIA COLI;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 84886249106     PISSN: 09639969     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.foodres.2013.01.062     Document Type: Review

References (162)

1. Andersen O.M., Markham K.R. Flavonoids: Chemistry, biochemistry, and applications 2006, CRC Taylor & Francis, Boca Raton.
2. Ajikumar P.K., Tyo K., Carlsen S., Mucha O., Phon T.H., Stephanopoulos G. Terpenoids: Opportunities for biosynthesis of natural product drugs using engineered microorganisms. Molecular Pharmaceutics 2008, 5:167-190.
3. Assini J.M., Mulvihill E.E., Huff M.W. Citrus flavonoids and lipid metabolism. Current Opinion in Lipidology 2013, 24:34-40.
4. Balsano C., Alisi A. Antioxidant effects of natural bioactive compounds. Current Pharmaceutical Design 2009, 15:3063-3073.
5. Battistuzzi F.U., Feijao A., Hedges S.B. A genomic timescale of prokaryote evolution: Insights into the origin of methanogenesis, phototrophy, and the colonization of land. BMC Evolutionary Biology 2004, 4:44.
6. Baumgart M., Dogan B., Rishniw M., Weitzman G., Bosworth B., Yantiss R., et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME Journal 2007, 1:403-418.
7. Belardinelli R., Muçaj A., Lacalaprice F., Solenghi M., Seddaiu G., Principi F., et al. Coenzyme Q10 and exercise training in chronic heart failure. European Heart Journal 2006, 27:2675-2681.
8. Bentley R., Meganathan R. Biosynthesis of vitamin K (menaquinone) in bacteria. Microbiological Reviews 1982, 46:241-280.
9. Benzer S. On the topography of the genetic fine structure. Proceedings of the National academy of Sciences of the United States of America 1961, 47:403-415.
10. Bessette P., Åslund F., Beckwith J., Georgiou G. Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm. Proceedings of the National academy of Sciences of the United States of America 1999, 96:13703-13708.
11. Birt D.F., Hendrich S., Wang W. Dietary agents in cancer prevention: Flavonoids and isoflavonoids. Pharmacology and Therapeutics 2001, 90:157-177.
12. Blattner F.R., Plunkett G., Bloch C., Perna N., Burland V., Riley M., et al. The complete genome sequence of Escherichia coli K-12. Science 1997, 277:1453-1462.
13. Brüssow H., Canchaya C., Hardt W.D. Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiology and Molecular Biology Reviews 2004, 68:560-602.
14. Caltagirone S., Rossi C., Poggi A., Ranelletti F.O., Natali P.G., Brunetti M., et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. International Journal of Cancer 2000, 87:595-600.
15. Castelli S., Coletta A., D'Annessa I., Fiorani P., Tesauro C., Desideri A. Interaction between natural compounds and human topoisomerase I. Biological Chemistry 2012, 393:1327-1340.
16. Clermont O., Bonacorsi S., Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Applied and Environmental Microbiology 2000, 66:4555-4558.
17. Cooper J.M., Schapira A.H. Friedreich's ataxia: coenzyme Q10 and vitamin E therapy. Mitochondrion 2007, 7:S127-S135.
18. Corcoran M.P., McKay D.L., Blumberg J.B. Flavonoid basics: Chemistry, sources, mechanisms of action, and safety. Journal of Nutrition in Gerontology and Geriatrics 2012, 31:176-189.
19. Cornelis P. Expressing genes in different Escherichia coli compartments. Current Opinion in Biotechnology 2000, 11:450-454.
20. Cushnie T.P., Lamb A.J. Recent advances in understanding the antibacterial properties of flavonoids. International Journal of Antimicrobial Agents 2011, 38:99-107.
21. Desjardins P., Picard B., Kaltenbock B., Elion J., Denamur E. Sex in Escherichia coli does not disrupt the clonal structure of the population: Evidence from random amplified polymorphic DNA and restriction-fragment-length polymorphism. Journal of Molecular Evolution 1995, 40:440-448.
22. Du J., Shao Z., Zhao H. Engineering microbial factories for synthesis of value-added products. Journal of Industrial Microbiology and Biotechnology 2011, 38:873-890.
23. Duriez P., Clermont O., Bonacorsi S., Bingen E., Chaventré A., Elion J., et al. Commensal Escherichia coli isolates are phylogenetically distributed among geographically distinct human populations. Microbiology 2001, 147:1671-1676.
24. Eckburg P.B., Bik E.M., Bernstein C.N., Purdom E., Dethlefsen L., Sargent M., et al. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
25. Elson C.E., Maltzman T.H., Boston J.L., Tanner M.A., Gould M.N. Anti-carcinogenic activity of d-limonene during the initiation and promotion/progression stages of DMBA-induced rat mammary carcinogenesis. Carcinogenesis 1988, 9:331-332.
26. Ehrlich G., Hu F., Shen K., Stoodley P., Post J. Bacterial plurality as a general mechanism driving persistence in chronic infections. Clinical Orthopaedics and Related Research 2005, 437:20-24.
27. Evans Doyle J., Evans Dolores G. Escherichia coli. Medical microbiology 1996, The University of Texas Medical Branch at Galveston. 4th ed.
28. Falkow S. The evolution of pathogenicity in E. coli, Shigella spp., and Salmonella spp. In Escherichia coli and Salmonella: Cellular and Molecular Biology 1996, 2723-2769. American Society for Microbiology, Washington, DC. 2nd ed. F.C. Neidhardt (Ed.).
29. Finlay B.B., Falkow S. Common themes in microbial pathogenicity revisited. Microbiology and Molecular Biology Reviews 1997, 61:136-169.
30. Forkmann G., Martens S. Metabolic engineering and applications of flavonoids. Current Opinion in Biotechnology 2001, 12:155-160.
31. Fotadar U., Zaveloff P., Terracio L. Growth of Escherichia coli at elevated temperatures. Journal of Basic Microbiology 2005, 45:403-404.
32. Fowler Z.L., Gikandi W.W., Koffas M.A. Increased malonyl coenzyme A biosynthesis by tuning the Escherichia coli metabolic network and its application to flavanone production. Applied and Environmental Microbiology 2009, 75:5831-5839.
33. Frense D. Taxanes: Perspectives for biotechnological production. Applied Microbiology and Biotechnology 2007, 73:1233-1240.
34. Fu Z., Gilbert E.R., Pfeiffer L., Zhang Y., Fu Y., Liu D. Genistein ameliorates hyperglycemia in a mouse model of nongenetic type 2 diabetes. Applied Physiology, Nutrition and Metabolism 2012, 37:480-488.
35. Furlong J.J.P., Nudelman N.S. Mechanism of cyclization of substituted 2'-hydroxychalcones to flavanones. Journal of the Chemical Society, Perkin Transactions 1985, 2:633-639.
36. Fux C.A., Shirtliff M., Stoodley P., Costerton J.W. Can laboratory reference strains mirror "real-world" pathogenesis?. Trends in Microbiology 2005, 13:58-63.
37. Gaziano J.M., Manson J.E., Branch L.G., Colditz G.A., Willett W.C., Buring J.E. A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Annals of Epidemiology 1995, 5:255-260.
38. Goto T., Takahashi N., Hirai S., Kawada T. Various terpenoids derived from herbal and dietary plants function as PPAR modulators and regulate carbohydrate and lipid metabolism. PPAR Research 2010, 2010:483958.
39. Goulinet S., Chapman M.J. Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 1997, 17:786-796.
40. Grozdanov L., Raasch C., Schulze J., Sonnenborn U., Gottschalk G., Hacker J., et al. Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. Journal of Bacteriology 2004, 186:5432-5441.
41. Haag J.D., Lindstrom M.J., Gould M.N. Limonene-induced regression of mammary carcinomas. Cancer Research 1992, 52:4021-4026.
42. Harborne J.B., Williams C.A. Advances in flavonoid research since 1992. Phytochemistry 2000, 55:481-504.
43. Heaton J.C., Jones K. Microbial contamination of fruit and vegetables and the behaviour of enteropathogens in the phyllosphere: A review. Journal of Applied Microbiology 2008, 104:613-626.
44. Hershey A.D., Powers S.W., Vockell A.L., Le Cates S.L., Ellinor P.L., Segers B.D., et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 2007, 47:73-80.
45. Herzer P.J., Inouye S., Inouye M., Whittam T.S. Phylogenetic distribution of branched RNA-linked multicopy single-stranded DNA among natural isolates of Escherichia coli. Journal of Bacteriology 1990, 172:6175-6181.
46. Huang C.J., Lin H., Yang X. Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. Journal of Industrial Microbiology and Biotechnology 2012, 39:383-399.
47. Hudault S., Guignot J., Servin A.L. Escherichia coli strains colonizing the gastrointestinal tract protect germ-free mice against Salmonella typhimurium infection. Gut 2001, 49:47-55.
48. Hwang E.I., Kaneko M., Ohnishi Y., Horinouchi S. Production of plant-specific flavanones by Escherichia coli containing an artificial gene cluster. Applied and Environmental Microbiology 2003, 69:2699-2706.
49. Ihssen J., Kowarik M., Dilettoso S., Tanner C., Wacker M., Thöny-Meyer L. Production of glycoprotein vaccines in Escherichia coli. Microbial Cell Factories 2010, 9:494-497.
50. Ingledew W.J., Poole R.K. The respiratory chains of Escherichia coli. Microbiological Reviews 1984, 48:222-271.
51. Inui M., Ooe M., Fujii K., Matsunaka H., Yoshida M., Ichihashi M. Mechanisms of inhibitory effects of CoQ10 on UVB-induced wrinkle formation in vitro and in vivo. Biofactors 2008, 32:237-243.
52. Ishii S., Sadowsky M.J. Escherichia coli in the environment: Implications for water quality and human health. Microbes and Environments 2008, 23:101-108.
53. Jang H.J., Yoon S.H., Ryu H.K., Kim J.H., Wang C.L., Kim J.Y., et al. Retinoid production using metabolically engineered Escherichia coli with a two-phase culture system. Microbial Cell Factories 2011, 10:59.
54. Jansen F.H. The herbal tea approach for artemisinin as a therapy for malaria?. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006, 100:285-286.
55. Jiang H., Wood K.V., Morgan J.A. Metabolic engineering of the phenylpropanoid pathway in Saccharomyces cerevisiae. Applied and Environmental Microbiology 2005, 71:2962-2969.
56. Kamada N., Inoue N., Hisamatsu T., Okamoto S., Matsuoka K., Sato T., et al. Nonpathogenic Escherichia coli strain Nissle 1917 prevents murine acute and chronic colitis. Inflammatory Bowel Diseases 2005, 11:455-463.
57. Kaneko M., Hwang E.I., Ohnishi Y., Horinouchi S. Heterologous production of flavanones in Escherichia coli: Potential for combinatorial biosynthesis of flavonoids in bacteria. Journal of Industrial Microbiology and Biotechnology 2003, 30:456-461.
58. Kaneko M., Ohnishi Y., Horinouchi S. Cinnamate:coenzyme A ligase from the filamentous bacterium Streptomyces coelicolor A3 (Ajikumar et al., 2008). Journal of Bacteriology 2003, 185:20-27.
59. Keymer J.E., Galajda P., Muldoon R., Austin R. Bacterial metapopulations in nanofabricated landscapes. Proceedings of the National academy of Sciences of the United States of America 2006, 103:17290-17295.
60. Kim D.H., Kim B.G., Jung N.R., Ahn J.H. Production of genistein from naringenin using Escherichia coli containing isoflavone synthase-cytochrome P450 reductase fusion protein. Journal of Microbiology and Biotechnology 2009, 19:1612-1616.
61. Kirby J., Keasling J.D. Biosynthesis of plant isoprenoids: Perspectives for microbial engineering. Annual Review of Plant Biology 2009, 60:335-355.
62. Kobayashi Y., Akita M., Sakamoto K., Liu H.F., Shigeoka T., Koyano T., et al. Large-scale production of anthocyanin by Aralia-cordata cell-suspension cultures. Applied Microbiology and Biotechnology 1993, 40:215-218.
63. Kohlmeier L., Kark J.D., Gomez-Gracia E., Martin B.C., Steck S.E., Kardinaal A.F., et al. Lycopene and myocardial infarction risk in the EURAMIC study. American Journal of Epidemiology 1997, 146:618-626.
64. Koli P., Sudan S., Fitzgerald D., Adhya S., Kar S. Conversion of commensal Escherichia coli K-12 to an invasive form via expression of a mutant histone-like protein. MBio 2011, 2.
65. Kubitschek H.E. Cell volume increase in Escherichia coli after shifts to richer media. Journal of Bacteriology 1990, 172:94-101.
66. Kumazawa T., Kimura T., Matsuba S., Sato S., Onodera J. Synthesis of 8-C-glucosylflavones. Carbohydrate Research 2001, 334:183-193.
67. Lawrence J.G., Ochman H. Molecular archaeology of the Escherichia coli genome. Proceedings of the National academy of Sciences of the United States of America 1998, 95:9413-9417.
68. Lecointre G., Rachdi L., Darlu P., Denamur E. Escherichia coli molecular phylogeny using the incongruence length difference test. Molecular and Biological Evolution 1998, 15:1685-1695.
69. Lederberg J., Tatum E.L. Gene recombination in E. coli. Nature 1946, 158:558.
70. Lee S.Y. High cell-density culture of Escherichia coli. Trends in Biotechnology 1996, 14:98-105.
71. Lee J.H., Koo T.H., Yoon H., Jung H.S., Jin H.Z., Lee K., et al. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochemical Pharmacology 2006, 72:1311-1321.
72. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). Journal of Biological Chemistry 1995, 270:12953-12956.
73. Leiherer A., Mundlein A., Drexel H. Phytochemicals and their impact on adipose tissue inflammation and diabetes. Vascular Pharmacology 2013, 58:3-20.
74. Leonard E., Lim K.H., Saw P.N., Koffas M.A. Engineering central metabolic pathways for high-level flavonoid production in Escherichia coli. Applied and Environmental Microbiology 2007, 73:3877-3886.
75. Leonard E., Yan Y., Fowler Z.L., Li Z., Lim C.G., Lim K.H., et al. Strain improvement of recombinant Escherichia coli for efficient production of plant flavonoids. Molecular Pharmaceutics 2008, 5:257-265.
76. Liby K.T., Yore M.M., Sporn M.B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nature Reviews Cancer 2007, 7:357-369.
77. Lim S.S., Jung S.H., Ji J., Shin K.H., Keum S.R. Synthesis of flavonoids and their effects on aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues. Journal of Pharmacy and Pharmacology 2001, 53:653-668.
78. Lukjancenko O., Wassenaar T.M., Ussery D.W. Comparison of 61 sequenced Escherichia coli genomes. Microbial Ecology 2010, 60:708-720.
79. Malla S., Koffas M.A., Kazlauskas R.J., Kim B.G. Production of 7-O-methyl aromadendrin, a medicinally valuable flavonoid, in Escherichia coli. Applied and Environmental Microbiology 2012, 78:684-694.
80. Makhija N., Sendasgupta C., Kiran U., Lakshmy R., Hote M.P., Choudhary S.K., et al. The role of oral coenzyme Q10 in patients undergoing coronary artery bypass graft surgery. Journal of Cardiothoracic and Vascular Anesthesia 2008, 22:832-839.
81. Maltzman T.H., Hurt L.M., Elson C.E., Tanner M.A., Gould M.N. The prevention of nitrosomethylurea induced mammary tumors by d-limonene and orange oil. Carcinogenesis 1989, 10:781-783.
82. Martin V.J., Pitera D.J., Withers S.T., Newman J.D., Keasling J.D. Engineering a mevalonate pathway in Escherichia coli for production of terpenoids. Nature Biotechnology 2003, 21:796-802.
83. Martinez A., Bradley A.S., Waldbauer J.R., Summons R.E., DeLong E.F. Proteorhodopsin photosystem gene expression enables photophosphorylation in a heterologous host. Proceedings of the National Academy of Sciences 2007, 104:5590-5595.
84. Manco M., Putignani L., Bottazzo G.F. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocrine Reviews 2010, 31:817-844.
85. Maurelli A.T., Fernandez R.E., Bloch C.A., Rode C.K., Fasano A. Black holes and bacterial pathogenicity: a large genomic deletion that enhances the virulence of Shigella spp. and enteroinvasive Escherichia coli. Proceedings of the National academy of Sciences of the United States of America 1998, 95:3943-3948.
86. Misawa N. Pathway engineering for functional isoprenoids. Current Opinion in Biotechnology 2011, 22:627-633.
87. Mitchell W. Natural products from synthetic biology. Current Opinion in Chemical Biology 2011, 15:505-515.
88. Miyahisa I., Kaneko M., Funa N., Kawasaki H., Kojima H., Ohnishi Y., et al. Efficient production of (2S)-flavanones by Escherichia coli containing an artificial biosynthetic gene cluster. Applied Microbiology and Biotechnology 2005, 68:498-504.
89. Moore B.S., Hopke J.N. Discovery of a new bacterial polyketide biosynthetic pathway. Chembiochem 2001, 2:35-38.
90. Mordente A., Guantaio B., Meucci E., Silvestrini A., Lombardi E., Martorana G.E., et al. Lycopene and cardiovascular diseases: An update. Current Medicinal Chemistry 2011, 18:1146-1163.
91. Mühldorfer I., Hacker J. Genetic aspects of Escherichia coli virulence. Microbial Pathogenesis 1994, 16:171-181.
92. Muntendam R., Melillo E., Ryden A., Kayser O. Perspectives and limits of engineering the isoprenoid metabolism in heterologous hosts. Applied Microbiology and Biotechnology 2009, 84:1003-1019.
93. Mutoh M., Takahashi M., Fukuda K., Matsushima-Hibiya Y., Mutoh H., Sugimura T., et al. Suppression of cyclooxygenase-2 promoter-dependent trascriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis 2000, 21:959-963.
94. Nicolle L.E. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. The Urologic Clinics of North America 2008, 35:1-12.
95. Ochman H., Selander R.K. Standard reference strains of Escherichia coli from natural populations. Journal of Bacteriology 1984, 157:690-693.
96. Orskov I., Orskov F., Jann B., Jann K. Serology, chemistry, and genetics of O and K antigens of Escherichia coli. Bacteriological Reviews 1977, 41:667-710.
97. Ortsater H., Grankvist N., Wolfram S., Kuehn N., Sjoholm A. Diet supplementation with green tea extract epigallocatechin gallate prevents progression to glucose intolerance in db/db mice. Nutrition and Metabolism 2012, 9:11.
98. Palozza P., Parrone N., Simone R.E., Catalano A. Lycopene in atherosclerosis prevention: An integrated scheme of the potential mechanisms of action from cell culture studies. Archives of Biochemistry and Biophysics 2010, 504:26-33.
99. Panchal S.K., Poudyal H., Brown L. Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats. Journal of Nutrition 2012, 142:1026-1032.
100. Paterson I., Anderson E.A. Chemistry. The renaissance of natural products as drug candidates. Science 2005, 310:451-453.
101. Peck R.F., Echavarri-Erasun C., Johnson E.A., Ng W.V., Kennedy S.P., Hood L., et al. brp and blh are required for synthesis of the retinal cofactor of bacteriorhodopsin in Halobacterium salinarum. Journal of Biological Chemistry 2001, 276:5739-5744.
102. Pfeuffer M., Auinger A., Bley U., Kraus-Stojanowic I., Laue C., Winkler P., et al. Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammatory parameters in men with different APOE isoforms. Nutrition, Metabolism, and Cardiovascular Diseases 2011, (Epub ahead of print). http://dx.doi.org/10.1016/j.numecd.2011.08.010.
103. Prior R.L., Lazarus S.A., Cao G., Muccitelli H., Hammerstone J.F. Identification of procyanidins and anthocyanins in blueberries and cranberries (Vaccinium spp.) using high-performance liquid chromatography/mass spectrometry. Journal of Agricultural and Food Chemistry 2001, 49:1270-1276.
104. Pupo G.M., Lan R., Reeves P.R. Multiple independent origins of Shigella clones of Escherichia coli and convergent evolution of many of their characteristics. Proceedings of the National academy of Sciences of the United States of America 2000, 97:10567-10572.
105. Qi L.W., Liu E.H., Chu C., Peng Y.B., Cai H.X., Li P. Anti-diabetic agents from natural products-An update from 2004 to 2009. Current Topics in Medicinal Chemistry 2010, 10:434-457.
106. Quinzii C.M., Lòpez L.C., Naini A., DiMauro S., Hirano M. Human CoQ10 deficiencies. Biofactors 2008, 32:113-118.
107. Quinzii C.M., Lòpez L.C., Von-Moltke J., Naini A., Krishna S., Schuelke M., et al. Respiratory chain dysfunction and oxidative stress correlate with severity of primary CoQ10 deficiency. The FASEB Journal 2008, 22:1874-1885.
108. Ranelletti F.O., Maggiano N., Serra F.G., Ricci R., Larocca L.M., Lanza P., et al. Quercetin inhibits p21-ras expression in human colon cancer cell lines and in primary colorectal tumors. International Journal of Cancer 2000, 85:438-445.
109. Reid G., Howard J., Gan B.S. Can bacterial interference prevent infection?. Trends in Microbiology 2001, 9:424-428.
110. Ro D.K., Douglas C.J. Reconstitution of the entry point of plant phenylpropanoid metabolism in yeast (Saccharomyces cerevisiae): implications for control of metabolic flux into the phenylpropanoid pathway. Journal of Biological Chemistry 2004, 279:2600-2607.
111. Roberts S.C. Production and engineering of terpenoids in plant cell culture. Nature Chemical Biology 2007, 3:387-395.
112. Rolhion N., Darfeuille-Michaud A. Adherent-invasive Escherichia coli in inflammatory bowel disease. Inflammatory Bowel Diseases 2007, 13:1277-1283.
113. Russo P., Del Bufalo A., Cesario A. Flavonoids acting on DNA topoisomerases: recent advances and future perspectives in cancer therapy. Current Medicinal Chemistry 2012, 19:5287-5293.
114. Russo P., Cesario A. Flavonoids in cancer therapy. Current Medicinal Chemistry 2012, (Epub ahead of print).
115. Sabehi G., Loy A., Jung K.H., Partha R., Spudich J.L., Isaacson T., et al. New insights into metabolic properties of marine bacteria encoding proteorhodopsins. PLoS Biology 2005, 3:e273.
116. Sacchettini J.C., Poulter C.D. Creating isoprenoid diversity. Science 1997, 277:1788-1789.
117. Santapaola D., Casalino M., Petrucca A., Presutti C., Zagaglia C., Berlutti F., et al. Enteroinvasive Escherichia coli virulence-plasmid-carried apyrase (apy) and ospB genes are organized as a bicistronic operon and are subject to differential expression. Microbiology 2002, 148:2519-2529.
118. Savageau M.A. Escherichia coli habitats, cell types, and molecular mechanisms of gene control. American Naturalist 1983, 122:732-744.
119. Sesso H.D., Liu S., Gaziano M., Buring J.E. Dietary lycopene, tomato based food products and cardiovascular disease in women. Journal of Nutrition 2003, 133:2336-2341.
120. Sethi G., Ahn K.S., Pandey M.K., Aggarwal B.B. Celastrol, a novel triterpene, potentiates TNF induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007, 109:2727-2735.
121. Si W., Gong J., Tsao R., Kalab M., Yang R., Yin Y. Bioassay-guided purification and identification of microbial components in Chinese green tea extracts. Journal of Chromatography. A 2006, 2006(1125):204-210.
122. Simone R.E., Russo M., Catalano A., Monego G., Froehlich K., Boehm V., et al. Lycopene inhibits NF-kB-mediated IL-8 expression and changes redox and PPARγ signalling in cigarette smoke-stimulated macrophages. PLoS One 2011, 6:e19652.
123. Sokurenko E.V., Chesnokova V., Dykhuizen D.E., Ofer I., Wu X.R., Krogfelt K.A., et al. Pathogenic adaptation of Escherichia coli by natural variation of the FimH adhesin. Proceedings of the National academy of Sciences of the United States of America 1998, 95:8922-8926.
124. Spagnolo C., Russo M., Bigotto S., Tedesco I., Laratta B., Russo G.L. Dietary polyphenols in cancer prevention: the example of the flavonoid quercetin in leukemia. Annals of the New York Academy of Sciences 2012, 1259:95-103.
125. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf K., Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088-2093.
126. Sun J. d-limonene: Safety and clinical applications. Alternative Medicine Review 2007, 12:259-264.
127. Surh Y.J. Cancer chemoprevention with dietary phytochemicals. Nature Reviews 2003, 3:768-780.
128. Tanaka H., Stohlmeyer M.M., Wandless T.J., Taylor L.P. Synthesis of flavonol derivatives as probes of biological processes. Tetrahedron Letters 2000, 41:9735-9739.
129. Tanaka H., Miyoshi H., Chuang Y.C., Ando Y., Takahashi T. Solid-phase synthesis of epigallocatechin gallate derivatives. Angewandte Chemie (International Ed. in English) 2007, 46:5934-5937.
130. Tanaka T., Shnimizu M., Moriwaki H. Cancer chemoprevention by carotenoids. Molecules 2012, 17:3202-3242.
131. Takahashia N., Kawadaa T., Gotoa T., Yamamotoa T., Taimatsua A., Matsuia N., et al. Dual action of isoprenols from herbal medicines on both PPARγ and PPARα in 3T3-L1 adipocytes and HepG2 hepatocytes. FEBS Letters 2002, 514:315-322.
132. Tapiero H., Townsend D.M., Tew K.D. The role of carotenoids in the prevention of human pathologies. Biomedicine and Pharmacotherapy 2004, 58:100-110.
133. Tauschek M., Gorrell R.J., Strugnell R.A., Robins-Browne R.M. Identification of a protein secretory pathway for the secretion of heat-labile enterotoxin by an enterotoxigenic strain of Escherichia coli. PNAS 2002, 99:7066-7071.
134. Tenaillon O., Skurnik D., Picard B., Denamur E. The population genetics of commensal Escherichia coli. Nature Reviews Microbiology 2010, 8:207-217.
135. Tsao R., Yang R., Young J.C., Zhu H. Polyphenolic profiles in eight apple cultivars using high-performance liquid chromatography (HPLC). Journal of Agricultural and Food Chemistry 2003, 51:6347-6353.
136. Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients 2010, 2:1231-1246.
137. Tsuruta H., Paddon C.J., Eng D., Lenihan J.R., Horning T., Anthony L.C., et al. High-level production of amorpha-4,11-diene, a precursor of the antimalarial agent artemisinin, in Escherichia coli. PLoS One 2009, 4:e4489.
138. Ueda K., Kim K.M., Beppu T., Horinouchi S. Overexpression of a gene cluster encoding a chalcone synthase-like protein confers redbrown pigment production in Streptomyces griseus. Journal of Antibiotics (Tokyo) 1995, 48:638-646.
139. van Poppel G. Epidemiological evidence for β-carotene in prevention of cancer and cardiovascular disease. European Journal of Clinical Nutrition 1996, 50:S57-S61.
140. Vidal O., Longin R., Prigent-Combaret C., Dorel C., Hooreman M., Lejeune P. Isolation of an Escherichia coli K-12 mutant strain able to form biofilms on inert surfaces: Involvement of a new ompR allele that increases curli expression. Journal of Bacteriology 1998, 180:2442-2449.
141. Vigushin D.M., Poon G.K., Boddy A., English J., Halbert G.W., Pagonis C., et al. Phase I and pharmacokinetic study of d-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemotherapy and Pharmacology 1998, 42:111-117.
142. Wacker M., Linton D., Hitchen P.G., Nita-Lazar M., Haslam S.M., North S.J., et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 2002, 298:1790-1793.
143. Wan S.B., Chan T.H. Enantioselective synthesis of afzelechin and epiafzelechin. Tetrahedron 2004, 60:8207-8211.
144. Wang H.K. The therapeutic potential of flavonoids. Expert Opinion on Investigational Drugs 2000, 9:2103-2119.
145. Wang Y., Chen S., Yu O. Metabolic engineering of flavonoids in plants and microorganisms. Applied Microbiology and Biotechnology 2011, 91:949-956.
146. Xia X., Weng J. Targeting metabolic syndrome: candidate natural agents. Journal of Diabetes 2010, 2:243-249.
147. Xie W., Du L. Diabetes is an inflammatory disease: Evidence from traditional Chinese medicines. Diabetes, Obesity & Metabolism 2011, 13:289-301.
148. Yan Y.J., Kohli A., Koffas M.A.G. Biosynthesis of natural flavanones in Saccharomyces cerevisiae. Applied and Environmental Microbiology 2005, 71:5610-5613.
149. Yan Y., Li Z., Koffas M.A. High-yield anthocyanin biosynthesis in engineered Escherichia coli. Biotechnology and Bioengineering 2008, 100:126-140.
150. Yang H., Chen D., Cui Q.C., Yuan X., Dou Q.P. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine", is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Research 2006, 66:4758-4765.
151. Yoon J.A., Kim B.G., Lee W.J., Lim Y., Chong Y., Ahn J.H. Production of a novel quercetin glycoside through metabolic engineering of Escherichia coli. Applied and Environmental Microbiology 2012, 78:4256-4262.
152. Yun C.H., Yim S.K., Kim D.H., Ahn T. Functional expression of human cytochrome P450 enzymes in Escherichia coli. Current Drug Metabolism 2006, 7:411-429.
153. Zha W., Rubin-Pitel S.B., Shao Z., Zhao H. Improving cellular malonyl-CoA level in Escherichia coli via metabolic engineering. Metabolic Engineering 2009, 11:192-198.
154. Zhaxybayeva O., Doolittle W.F. Lateral gene transfer. Current Biology 2011, 21:R242-R246.
155. Zhong J.J., Seki T., Kinoshita S., Yoshida T. Effect of light irradiation on anthocyanin production by suspended culture of Perilla-frutescens. Biotechnology and Bioengineering 1991, 38:653.
156. http://www.gsbs.utmb.edu/microbook/ch025.htm.
157. http://textbookofbacteriology.net/e.coli_2.html.
158. http://www.who.int/vaccine_research/diseases/diarrhoeal/en/index4.html.
159. http://www.mgc.ac.cn/.
160. http://www.cdc.gov/ecoli/index.html/.
161. http://www.ncbi.nlm.nih.gov/genome/browse/.
162. http://myxo.css.msu.edu/lenski/pdf/1988,%20Evolution,%20I,%20Lenski.pdf.